trending Market Intelligence /marketintelligence/en/news-insights/trending/9xf9wit_p73j3c61tpbqvq2 content esgSubNav
In This List

Forendo Pharma bags €4M funding from private equity firm

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Forendo Pharma bags €4M funding from private equity firm

Forendo Pharma Ltd. received a €4 million funding from private equity firm Vesalius Biocapital III.

Vesalius Biocapital III Partners is a fund managed by Vesalius Biocapital Partners S.à r.l. and invests in later stage European life science companies in drug development, medtech, diagnostics and eHealth.

As part of the investment, Vesalius' Managing Partner Stéphane Verdood will join the Forendo Pharma board.

The funding enables Forendo, a portfolio company of Karolinska Development AB, to accelerate development of its women's health product candidates.

The company's lead program, known as FOR 6219, is being developed to treat endometriosis — a gynecological disorder that affects up to 10% of women in reproductive age.